M
Meir Schechter
Researcher at Hebrew University of Jerusalem
Publications - 32
Citations - 210
Meir Schechter is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 13 publications receiving 93 citations. Previous affiliations of Meir Schechter include Hadassah Medical Center.
Papers
More filters
Journal ArticleDOI
Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson's Disease.
Suaad Abd-Elhadi,Asaf Honig,Dganit Simhi-Haham,Meir Schechter,Eduard Linetsky,Tamir Ben-Hur,Ronit Sharon +6 more
TL;DR: The first evidence for an association between RBCs-expressed α-Syn and pathogenic mechanisms involved in PD is found, and a significantly lower ratio of total-to-proteinase K-resistant α-syn levels was detected in PD patients than in the healthy control group.
Journal ArticleDOI
α-Synuclein Translocates to the Nucleus to Activate Retinoic-Acid-Dependent Gene Transcription.
TL;DR: Nuclear translocation of α-Syn following RA treatment enhances its toxicity in cultured neurons and the expression levels of PD-associated genes, including ATPase cation transporting 13A2 (ATP13A2) and PTEN-induced kinase1 (PINK1).
Journal ArticleDOI
α-Synuclein facilitates endocytosis by elevating the steady-state levels of phosphatidylinositol 4,5-bisphosphate
TL;DR: Evidence is provided for a critical involvement of PIPs in α- Syn–mediated membrane trafficking and the rate of synaptic vesicle endocytosis is differentially affected by the α-Syn mutations and associates with their effects on PI(4,5)P2 levels, however, with the exception of the A30P mutation.
Journal ArticleDOI
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
Ofri Mosenzon,Ofri Mosenzon,Stefano Del Prato,Meir Schechter,Meir Schechter,Lawrence A. Leiter,Antonio Ceriello,Ralph A. DeFronzo,Itamar Raz,Itamar Raz +9 more
TL;DR: In this article, the authors defined SGLT2i and GLP-1 RA as diabetes/disease modifying drugs (DMDs) and designed a SIMPLE approach in order to assist primary care teams in selecting the most appropriate therapy for their patients.
Journal ArticleDOI
A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease
Meir Schechter,Jessica Grigoletto,Suaad Abd-Elhadi,Hava Glickstein,Alexander Friedman,Geidy E. Serrano,Thomas G. Beach,Ronit Sharon +7 more
TL;DR: It is shown that through regulating PI4,5P 2 levels, α-Syn acts to elongate the main axon and collaterals, resulting in a higher density of axons in the striatal WMTs, at early stages of PD.